RxDoctor Payments Data

Ahmed Selim, MD

Clinical Cardiac Electrophysiology · Burleson, TXNPI 1386950368

Payments from drug & device makers

What this record shows

This record is dominated by grants: $102,500 of the $122,646 with a category attached, or 83.6%. 15 manufacturers reported payments, led by Biosense Webster, Inc. at 41.2% of the total. Reporting peaked in 2021 at $104,263 and has fallen 99.6% since, to $405 in 2025.

$122,646in general payments, 2019–2025

Across 207 payments — averaging $592.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$51K
  • Abbott$30K
  • Medtronic$28K
  • Biotronik Inc.$8K
  • Boston Scientific$5K
  • Inspire Medical Systems, Inc.$189
  • plus $590 from 9 others

What the payments were for

  • Grants$102,50084%
  • Travel & lodging$11,3259%
  • Food & beverage$8,3937%
  • Education$4280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$122,646 in reported general payments places this provider in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$265,388
Medicare patients
507
Services billed
2,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$129,687
MultaqDronedarone Hcl18$20,363
XareltoRivaroxaban16$10,392
Amiodarone Hcl149$1,636
SotalolSotalol Hcl66$1,335
Metoprolol Succinate70$1,137
Metoprolol Tartrate64$174
Potassium Chloride15$165
Sucralfate15$130
Pantoprazole Sodium13$92
Furosemide41$90
Losartan Potassium13$88
Lisinopril11$47
Atorvastatin Calcium13$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$113$129,687153 claims
Johnson & JohnsonXarelto$84$10,39216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Burleson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →